Evidence map›Paper›PMID 21655317›Full record

Trial reportPLoS medicine2011

The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial.

Beth P Kangwana, Sarah V Kedenge, Abdisalan M Noor, Victor A Alegana, Andrew J Nyandigisi, Jayesh Pandit, Greg W Fegan, James E Todd, Simon Brooker, Robert W Snow and 1 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PLoS medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 12 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 12 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Home- or community-based programmes for treating malaria.The Cochrane database of systematic reviews · 2013
    Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Beth P KangwanaMalaria Public Health & Epidemiology Group, Kenya Medical Research Institute-Wellcome Trust Research Programme, Kenya. bkangwana@nairobi.kemri-wellcome.org
Sarah V Kedenge
Abdisalan M Noor
Victor A Alegana
Andrew J Nyandigisi
Jayesh Pandit
Greg W Fegan
James E Todd
Simon Brooker
Robert W Snow
Catherine A Goodman
Kenya Medical Research Institute · KELondon School of Hygiene & Tropical Medicine · GBUniversity of Oxford · GBMinistry of Health · KEPharmacy and Poisons Board · KEUniversity of London · GB

Funding

Wellcome Trust 079080Wellcome Trust 079081Wellcome Trust 0811673Wellcome Trust 081829
6 · The paper itself

Abstract

backgroundIt has been proposed that artemisinin-based combination therapy (ACT) be subsidised in the private sector in order to improve affordability and access. This study in western Kenya aimed to evaluate the impact of providing subsidized artemether-lumefantrine (AL) through retail providers on the coverage of prompt, effective antimalarial treatment for febrile children aged 3-59 months. METHODS AND

findingsWe used a cluster-randomized, controlled design with nine control and nine intervention sublocations, equally distributed across three districts in western Kenya. Cross-sectional household surveys were conducted before and after the delivery of the intervention. The intervention comprised provision of subsidized packs of paediatric ACT to retail outlets, training of retail outlet staff, and community awareness activities. The primary outcome was defined as the proportion of children aged 3-59 months reporting fever in the past 2 weeks who started treatment with AL on the same day or following day of fever onset. Data were collected using structured questionnaires and analyzed based on cluster-level summaries, comparing control to intervention arms, while adjusting for other covariates. Data were collected on 2,749 children in the target age group at baseline and 2,662 at follow-up. 29% of children experienced fever within 2 weeks before the interview. At follow-up, the percentage of children receiving AL on the day of fever or the following day had risen by 14.6% points in the control arm (from 5.3% [standard deviation (SD): 3.2%] to 19.9% [SD: 10.0%]) and 40.2% points in the intervention arm (from 4.7% [SD: 3.4%] to 44.9% [SD: 11.7%]). The percentage of children receiving AL was significantly greater in the intervention arm at follow-up, with a difference between the arms of 25.0% points (95% confidence interval [CI]: 14.1%, 35.9%; unadjusted p = 0.0002, adjusted p = 0.0001). No significant differences were observed between arms in the proportion of caregivers who sought treatment for their child's fever by source, or in the child's adherence to AL.

conclusionsSubsidizing ACT in the retail sector can significantly increase ACT coverage for reported fevers in rural areas. Further research is needed on the impact and cost-effectiveness of such subsidy programmes at a national scale.

trial registrationCurrent Controlled Trials ISRCTN59275137 and Kenya Pharmacy and Poisons Board Ethical Committee for Clinical Trials PPB/ECCT/08/07.

Indexed as

Rural Health ServicesAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsChild, PreschoolCost-Benefit AnalysisCross-Sectional StudiesDrug CombinationsEthanolaminesFemaleFluorenesHealth Services AccessibilityHumansInfantKenyaMalaria, FalciparumAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsDrug CombinationsEthanolaminesFluorenes

Identifiers

PMID21655317
PMCPMC3104978
OpenAlexW2059750635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.